Welcome to the Program The world’s first and only weight loss device that requires no surgery, endoscopy, or anesthesia* • Placed during a brief 20-minute visit 1 and passes naturally after approximately 16 weeks 2* • Patients lose an average of 10 to 15kg and 10 to 15% TBWL after approximately 16 weeks of Elipse therapy 2 to 11 • 15,000 balloons distributed worldwide • The program includes professional follow-up over 6-months along with a smart scale and app to track weight loss.** *In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. **The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile. 1. Clinical Trial Reports: DAA069 and DAA105 | 2. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241. | 3. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182. | 4. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317. | 5. Machytka E et al. Endoscopy. 2017 Feb;49(2): 154-160. | 6. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-1 | 7. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22. | 8. Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA | 9. Genco et al. Submitted to SOARD. Abstract A185, presented at Obesity Week, 2018, Nashville, USA | 10. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain | 11. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States. This material is not intended for a U.S. audience. This material describes our product, which has not been approved or cleared for marketing by the U.S. Food and Drug Administration. Our product is not available for sale in the United States. TBWL: Total Body Weight Loss
34
Embed
Program · weight loss treatments than facial wrinkle treatments. Weight loss is the natural step beforebody contouring procedures: CoolSculpting, Liposuction, Abdominoplasty, Belkyra*
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Welcome to the
Program
The world’s first and only weight loss device that requires no surgery, endoscopy, or anesthesia*
• Placed during a brief 20-minute visit1 and passes naturally after approximately 16 weeks2*
• Patients lose an average of 10 to 15kg and 10 to 15% TBWL after approximately 16 weeks of Elipse therapy2 to 11
• 15,000 balloons distributed worldwide
• The program includes professional follow-up over 6-months along with a smart scale and app to track weight loss.**
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. **The Elipse Balloon must be used in conjunction with asupervised nutrition and behavior modification program. Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on thephysician and patient’s profile.
1. Clinical Trial Reports: DAA069 and DAA105 | 2. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241. | 3. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182. | 4. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317. | 5. Machytka E et al. Endoscopy. 2017 Feb;49(2): 154-160. | 6. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-1 | 7. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22. | 8. Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA | 9. Genco et al. Submitted to SOARD. Abstract A185, presented at Obesity Week, 2018, Nashville, USA | 10. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain | 11. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States. This material is not intended for a U.S. audience. This material describes our product, which has not been approved or cleared for marketing by the U.S. Food and Drug Administration. Our product is not available for sale in the United States.
TBWL: Total Body Weight Loss
Vast 2018 Consumer Research across Europe, Middle East, China and U.S.A.
Screening a representative panel of 9,800 patients
people are overweightor obese in the US, EU5, China and the UAE*
1 3are not fully satisfiedwith previously trieddiet plans2
78%are not fully satisfiedwith previously triedweight loss solutions1
76%
An increasing number of patients lack satisfying treatment options
2. Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q3C. On a scale of 1 to 10, where 1 isnot at all satisfied and 10 is extremely satisfied, how satisfied are you with the following? Think about your experience of the wholeprocess.Global level. Base: n=4831Satisfied: 8-10/10, neither 4-7/10, unsatisfied 1-3/10
1. Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018Q3C. On a scale of 1 to 10, where 1 is not at all satisfied and 10 is extremely satisfied, how satisfied are you with the following? Think about your experience of the whole process.Global level. Base: n=4831Satisfied: 8-10/10, neither 4-7/10, unsatisfied 1-3/10 *Based on WHO, Eurostat and US Census data
of those that wouldconsider HCP* intervention, would consider Elipse
60%
4.3% would consider the Elipse BalloonGlobally, 7.2% of eligible patients would considertreatment from an HCP to manage weight loss
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018, Population, Age, and Income Data takenfrom Census.gov Funnels computed using cascading base methodology Bothered by weight is determined at 4 – 7 on a 7 point scale Considerers needs to be assessed by medicalpractitioner to assess their eligibility to the treatment*HCP = Health Care Professional
Total population in consideredareas across 8 geographies
% OF OVERWEIGHT/OBESE CONSIDERING MEDICAL TREATMENT FOR THE MENTIONED FACIAL/BODY CONCERNS
Elipse is an aesthetic lifestyle treatment for moderateto high BMI patients
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q2B.Are you considering having any of the following facial or body treatments providedby a physician / healthcare professional in the next 2 years? Global level. Base: n=6394*The safety and effectiveness of the non-Elipse treatments has not been evaluated by AllurionTechnologies, Inc
more overweight and obese people considerweight loss treatments than facial wrinkle treatments
Weight loss is the natural step beforebodycontouring procedures: CoolSculpting, Liposuction, Abdominoplasty, Belkyra*
1. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.2. Avram and Harry Lasers Surg Med. 2009 Dec;41(10):703-8.3. Jacob et al. J Drugs Dermatol. 2018 Nov 1;17(11):1229-1232.4. Moradi and Palm. J Drugs Dermatol. 2015 Sep;14(9):982-5.
The safety and effectiveness of the non-Elipse treatments has not been evaluated by Allurion Technologies, Inc
Gastric balloon procedures have a reduced uptake due to the lackof patient friendly solutions
Perceived reasons for NOT considering a weight loss balloontreatment requiring endoscopyand anesthesia
Q16. When considering the weight loss balloon treatment requiring an endoscopy and anesthesia, why are you not interested in this treatment? Global data Base: Q16 n=2377, Q18A n=4341, Q18B n=4341
49% Risk of damage to throat/oesophagus
65%49% Don’t want anesthesia38% Discomfort29% Pain15% Downtime / Recovery time
3 times more patients would considerthe Elipse Balloonthan those who would considerbariatric surgery
Q4A. Have you ever discussed your weight with a health care professionalsuch as a [UK ONLY: GP/] [US ONLY: PCP] / doctor, specialist, dietician or nutritionist?Global data. Base: asked to all, n=8281
of those that wouldconsider HCP* intervention, would consider Elipse
60%
of those that would considerHCP intervention, would considerbariatric surgery
more patients would preferintragastric balloons placedby swallowing versus endoscopicplacement and removal by naturalpassage versus endoscopic*
6xwould only be willing to trya treatment that doesn’t requireany surgery or anesthesia
40%
Endoscopy, anesthesia and surgeryare major barriers to treatment for overweightand obese patients
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q11. Which of the following weight losstreatment options would you be willing to try if it was proven to bean effective weight loss treatment? Global data. Base: n=3687. Likely to ask HCP for solution not tried.
Q18A. What is your preference for how a weight loss balloonis placed in your stomach? Q18B. What is your preference for how a weight loss balloon at the end of your treatment is removed fromyour stomach? Global data Base: Q16 n=3028, Q18A n=6152, Q18B n=6152 Don’t know/ not sure were also included in the options to answer.*In rare cases, the Elipse Balloon may require endoscopicor surgical intervention for removal
DriversNon-surgical treatment is a key preference factor for those considering weight loss treatment
IMPORTANT FACTORS IN HCP INTERVENTION TREATMENTTop 6 most important
Q10. What would you be looking for from a physician/health care provider administered weight loss treatment?Global data. Base: n=2461. Likely to ask HCP for solution not tried.
Patients want to get resultsand achieve lifestyle changeswithout surgery, endoscopy or anesthesia
IMPORTANT FACTORS FOR HCP TREATMENT ACCORDING TO MARKET RESEARCH
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018Q10. What would you be looking for from a physician/ health care provider administered weight loss treatment? Global data. Base: n=2461Q19A. What do you like about the Elipse Balloon? Global data. Base: n=2538
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal
2. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.3. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182.4. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.5. Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160.6. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-17. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22.8. Ienca et al. Submitted to SOARD. Abstract A278, presentedat Obesity Week, 2018, Nashville, USA9. Genco et al. Submitted to SOARD. Abstract A185, presentedat Obesity Week, 2018, Nashville, USA10. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain11. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States.
**The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurionadvises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.
TBWL: Total Body Weight Loss
The Elipse Balloon is swallowedduring a brief 20 minute visit1 and passes naturally afterapproximately 16 weeks2*
Your patient enjoys the privacyof an outpatient treatment: no one in his or her circle needsto know they had the placement
01A swift experience
The first and only game-changingdevice that matches patients’ needsand expectations
After approximately 16 weeksof Elipse therapy, patients losean average of 10 to 15kgand 10 to 15% TBWL2 to 11.
Patients receive medical and nutritional support for the entire duration of the program along with a smartphone app and a connected scale**
Efficacy and safety of the Elipse Balloonhas been demonstrated in multiple clinical studies
1. Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160.2. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182.3. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-14. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22.5. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.
1. Ienca et al. Submitted to SOARD. Abstract A278,presented at Obesity Week, 2018, Nashville, USA2. Genco et al. Submitted to SOARD. Abstract A185,presented at Obesity Week, 2018, Nashville, USA3. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-12414. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain5. Raftopoulos et al. Abstract 1978. Presented at ACS 2019,San Francisco, United States.
Efficacy and safety of the Elipse Balloonhas been demonstrated in multiple clinical studies
YearPublished
n Mean StartingBMI (kg/m2)
WeightLoss
Expanding the Reach of Intragastric Balloons: First Multicenter Results of ElipseBalloon in Non-Core User Groups1
2019(Submittedfor publication)
64 35±4.6 After 4 months, at the time of excretion16 %TBL5.7↓ BMI
Intensive lifestylemodification includeda structuredcurriculum-basednutritional, exerciseand behaviormodification program
Lifestyle modificationWhen coupled with a 16-week intensive lifestylemodification, Elipse leads to significant weight lossvs. lifestyle modification alone1*.
1. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States.*The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program.Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.
0
10
20
30
40
50
60
70
80
% of patients achieving 10% TBWL
PERCENTAGE OF PATIENTS ACHIEVING 10% TBWL AT 16 WEEKS
Elipse Safety ProfileAllurion Internal Vigilance Data
≈ 98%No reportedadverse events
In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. Some individuals may not be eligible to receive the Elipse Balloon. Doctors take a detailed medical history and perform a physical examination to determine patients’ eligibility.
The Elipse Balloon is a temporary weight loss aid for adults over the age of 18 who are overweight or obese, defined as a body mass index (BMI) ≥ 27. The Elipse Balloon can only be administered by a healthcare professional who is knowledgeable about the use of the Elipse Balloon.
The Elipse Balloon must be used in conjunction with a supervisednutrition and behavior modification program. Allurion advisesa 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.
ADVERSE EVENTS RATES (%)MARCH 2016 – JUNE 2019
Total units distributed= 15,200
Total adverse events reported were lessthan 2% of total Elipse Balloons placed
In rare cases, the empty balloonmay be vomited instead of passing through the GI tract. Althoughstartling to the patient, vomitingof the balloon has not been associated with any reportedadverse events to date.
“Before, I was so big that I had a lot of difficulties with mobilityand there were days when I wouldn't be able to leave the house. Now, I feel like I have my life back again.”
Michael, 67, UK, in the Daily Mail
“I swallowed the capsule without too much difficulty —I felt a bit queasy but nothing more (…) I’ve lost 25 inches all over and I can fit into a size 16 comfortably.”
Kayleigh, 28, UK, in the Daily Mail – Spire Thames Valley Dr Humadi
“It was fantastic (...) I’ve lost 16 pounds in 4 weeks, my energy and my confidence are back, I’m fitting into clothesI haven’t worn for 30 years!”
Hetsie, 42, UK, on Channel 4
“I was going straight to obesity (…) I finished the treatment6 months ago but I still feel full faster than before. (…) I lost 20 kilos thanks to the Elipse Balloon.”
Véronique, 50, France, in Femme Actuelle
Actual Elipse Patient*Results may vary from one participant to another. A small percentage of patients don’t respond to the treatment.
Inspire others: share your patient success stories